These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38898050)

  • 1. The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer.
    Yan P; Lin X; Wu L; Xu L; Li F; Liu J; Xu F
    Nat Commun; 2024 Jun; 15(1):5255. PubMed ID: 38898050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
    Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
    Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
    Pillarisetti K; Edavettal S; Mendonça M; Li Y; Tornetta M; Babich A; Majewski N; Husovsky M; Reeves D; Walsh E; Chin D; Luistro L; Joseph J; Chu G; Packman K; Shetty S; Elsayed Y; Attar R; Gaudet F
    Blood; 2020 Apr; 135(15):1232-1243. PubMed ID: 32040549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma.
    Kodama T; Kochi Y; Nakai W; Mizuno H; Baba T; Habu K; Sawada N; Tsunoda H; Shima T; Miyawaki K; Kikushige Y; Mori Y; Miyamoto T; Maeda T; Akashi K
    Mol Cancer Ther; 2019 Sep; 18(9):1555-1564. PubMed ID: 31270154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
    Zhang M; Wei G; Zhou L; Zhou J; Chen S; Zhang W; Wang D; Luo X; Cui J; Huang S; Fu S; Zhou X; Tang Y; Ding X; Kuang J; He XP; Hu Y; Huang H
    Lancet Haematol; 2023 Feb; 10(2):e107-e116. PubMed ID: 36725117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models.
    Tomita U; Ishimoto Y; Ri M; Kawase Y; Hizukuri Y; Maru C; Nanai K; Nakamura R; Nakayama M; Oguchi-Oshima K; Sumi H; Ohtsuka T; Iida S; Agatsuma T
    Sci Rep; 2024 Mar; 14(1):5135. PubMed ID: 38429446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting GPRC5D in multiple myeloma.
    Elemian S; Al Hadidi S
    Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
    Xia J; Li Z; Xu K
    J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
    Lee H; Ahn S; Maity R; Leblay N; Ziccheddu B; Truger M; Chojnacka M; Cirrincione A; Durante M; Tilmont R; Barakat E; Poorebrahim M; Sinha S; McIntyre J; M Y Chan A; Wilson H; Kyman S; Krishnan A; Landgren O; Walter W; Meggendorfer M; Haferlach C; Haferlach T; Einsele H; Kortüm MK; Knop S; Alberge JB; Rosenwald A; Keats JJ; Rasche L; Maura F; Neri P; Bahlis NJ
    Nat Med; 2023 Sep; 29(9):2295-2306. PubMed ID: 37653344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPRC5D-Targeted CAR T Cells for Myeloma.
    Mailankody S; Devlin SM; Landa J; Nath K; Diamonte C; Carstens EJ; Russo D; Auclair R; Fitzgerald L; Cadzin B; Wang X; Sikder D; Senechal B; Bermudez VP; Purdon TJ; Hosszu K; McAvoy DP; Farzana T; Mead E; Wilcox JA; Santomasso BD; Shah GL; Shah UA; Korde N; Lesokhin A; Tan CR; Hultcrantz M; Hassoun H; Roshal M; Sen F; Dogan A; Landgren O; Giralt SA; Park JH; Usmani SZ; Rivière I; Brentjens RJ; Smith EL
    N Engl J Med; 2022 Sep; 387(13):1196-1206. PubMed ID: 36170501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPRC5D-Directed CAR Yields 100% Response Rate.
    Cancer Discov; 2022 Aug; 12(8):OF3. PubMed ID: 35748592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.
    Rinderknecht M; Villa A; Ballmer-Hofer K; Neri D; Detmar M
    PLoS One; 2010 Aug; 5(8):e11941. PubMed ID: 20689828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
    Xia J; Li H; Yan Z; Zhou D; Wang Y; Qi Y; Cao J; Li D; Cheng H; Sang W; Zhu F; Sun H; Chen W; Qi K; Yan D; Qiu T; Qiao J; Yao R; Liu Y; Wang X; Zhang Y; Peng S; Huang CH; Zheng J; Li Z; Chang AH; Xu K
    J Clin Oncol; 2023 May; 41(14):2583-2593. PubMed ID: 36881785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
    Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
    N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma.
    Liu Y; Zhou YQ; Nie L; Zhu SS; Li N; Wu ZH; Wang Q; Qi J; Wu BY; Chen SQ; Wang HB
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.
    Atamaniuk J; Gleiss A; Porpaczy E; Kainz B; Grunt TW; Raderer M; Hilgarth B; Drach J; Ludwig H; Gisslinger H; Jaeger U; Gaiger A
    Eur J Clin Invest; 2012 Sep; 42(9):953-60. PubMed ID: 22591013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bispecific antibodies in multiple myeloma].
    Escure G; Manier S
    Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.
    Derrien J; Gastineau S; Frigout A; Giordano N; Cherkaoui M; Gaborit V; Boinon R; Douillard E; Devic M; Magrangeas F; Moreau P; Minvielle S; Touzeau C; Letouzé E
    Nat Cancer; 2023 Nov; 4(11):1536-1543. PubMed ID: 37653140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an Antigen-Antibody Co-Display System for Detecting Interaction of G-Protein-Coupled Receptors and Single-Chain Variable Fragments.
    Zhang Y; Wu BJ; Yu X; Luo P; Ye H; Yu Y; Han W; Li J
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.